Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Riera

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2009
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junctionMichael Stahl, Martin K Walz, Martin Stuschke, et al.
BMC Cancer|July 23, 2024
Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trialMeinolf Karthaus, Volker Heinemann, Jorge Riera-Knorrenschild, et al.
Neuroimage|September 21, 2016
The neurogenesis of P1 and N1: A concurrent EEG/LFP studyMichael Bruyns-Haylett, Jingjing Luo, Aneurin J Kennerley, et al.
International Journal of Cancer|February 9, 2023
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN studyTobias Dechow, Jorge Riera-Knorrenschild, Björn Hackanson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2015
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische OnkologieSylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, et al.
BMC Cancer|June 19, 2023
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)Sylvie Lorenzen, Alix Schwarz, Claudia Pauligk, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
BMC Cancer|June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
International Journal of Cancer|March 6, 2024
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapyMichael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ StudyIvonne Haffner, Katrin Schierle, Elba Raimúndez, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2009
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junctionMichael Stahl, Martin K Walz, Martin Stuschke, et al.
BMC Cancer|July 23, 2024
Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trialMeinolf Karthaus, Volker Heinemann, Jorge Riera-Knorrenschild, et al.
Neuroimage|September 21, 2016
The neurogenesis of P1 and N1: A concurrent EEG/LFP studyMichael Bruyns-Haylett, Jingjing Luo, Aneurin J Kennerley, et al.
International Journal of Cancer|February 9, 2023
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN studyTobias Dechow, Jorge Riera-Knorrenschild, Björn Hackanson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2015
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische OnkologieSylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, et al.
BMC Cancer|June 19, 2023
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)Sylvie Lorenzen, Alix Schwarz, Claudia Pauligk, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
BMC Cancer|June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
International Journal of Cancer|March 6, 2024
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapyMichael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ StudyIvonne Haffner, Katrin Schierle, Elba Raimúndez, et al.
Pageof 8